Advanced searches left 3/3

Gadobenate Dimeglumine - Crossref

Summarized by Plex Scholar
Last Updated: 07 August 2022

* If you want to update the article please login/register

Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention

Object The aim of this essay was to determine 0. 1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine, also known as gadolinium diethylenetriamine pentaacetic acid, for enhanced magnetic resonance imaging of intraaxial brain tumors. Methods Eighty-four patients with either intraaxial glioma or metastasis underwent two MR imaging tests at 1. 5 tesla, one with Gd-BOPTA as the contrast agent and the other with Gd-DTPA. Administrations that were purely randomised contrast medium administrations were from 2 to 7 days. T 1 -weighted spin echo and T 2 -weighted fast spin echo images were obtained before the agents' administration of contrast agents and T 1 -weighted spin echo images were obtained. 84 patients were seen with images obtained with Gd-BOPTA contrast in four, 52, and 56 of 84 patients compared to those obtained with Gd-DTPA contrast in four, six, and three of 84 patients.

Source link: https://doi.org/10.3171/jns.2007.106.4.557


Anaphylaxis to Gadobenate Dimeglumine (Multihance®): A Case Report

Background: Gadolinium chelates are a common contrast media used in MRI. Methods: A 32-year-old female patient with a personal history of multiple sclerosis, undergone an MRI scan, developed bronchospasm and acute urticaria with diffusely large pruritic plaques in the first minute of Gd-BOPTA infusion. In the last two years, the patient reported two additional MRI scans with the clear use of unknown contrast media in the first two years with no adverse effects. Skin prick tests and intradermal tests were carried out using 1:1,000, 1:100, and 1:10 dilution of the offending agent and alternative gadolinium-based products [gadodiamide and gadoteric acid] respectively. The control group was made up of a group of ten nonatopic individuals who underwent the same skin testing. Tryptase concentration was significantly elevated 2 h after the reaction, compared to that at 48 h. We present the first instance of an allergic reaction to gadobenate dimeglumine.

Source link: https://doi.org/10.1159/000103227


Gadobenate dimeglumine and cerebral glucose metabolism: Continuous monitoring of striatal lactate levels in freely moving rats

Purpose: Brain contrast-enhanced MR imaging reveals the leakage of contrast material into the brain tissue as a result of blood-brain barrier disruption. Tolerability of the contrast agent must be high in brain tissue and contrast material. We investigated the neurotolerability of the paramagnetic CA gadobenate dimeglumine, which was specifically introduced into the corpus striatum of freely moving rats by assessing cerebral glucose metabolism based on lactate levels in the present study. Results: Gadobenate dimeglumine did not cause any significant changes in the lactate striatal profiles over the 30-min period following administration. Given aCSF, Lactate response in rats followed the same pattern as in rats. Conclusion: Gadobenate dimeglumine, intracerebrally administered, did not have an effect on cerebral glucose metabolism in rats, as it showed the same behavior as aCSF on cerebral glucose utilization.

Source link: https://doi.org/10.1080/028418500127345550


Incorporating the hepatobiliary phase of gadobenate dimeglumine-enhanced MRI in the diagnosis of hepatocellular carcinoma: increasing the sensitivity without compromising specificity

Diagnosis of hepatocellular carcinoma is based on wash-in of contrast during the arterial phase followed by washing out during the portal or delayed venous phase. Purpose: The aim of this paper is to investigate the role of the hepatobiliary phase of Gadobenate dimeglumine magnetic resonance imaging in identifying HCCs without the usual arterial growth and venous washout. Ninety-seven cirrhotic patients who underwent liver transplantation and Gd-BOPTA enhanced MRI within 3 months of surgery were retrospectively reviewed. Twenty-three of the 55 HCCs showing Pattern B were also hypocritical on the hepatobiliary phase. Pattern B1 matched with Pattern A raises the sensitivity of HCC classification from 46. 9% to 62. 8%, with no compromise on specificity. Conclusions Pattern B1 enhances HCC characterization in a variety of ways, with no compromise on the specificity.

Source link: https://doi.org/10.1177/0284185115616291


A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging with Hepatocyte-Specific Contrast Agents: Uses, Findings, and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine

In particular, contrast-enhanced MRI using hepatocyte-specific contrast agents enhances lesion detection and characterization as compared to other imaging modalities and MRI techniques. The clinical characteristics, protocols, and emerging uses of the two commercially available combined contrast agents available in the United States, gadoxetate disodium and gadobenate dimeglumine are discussed. Lastly, the pitfalls in the use of combined contrast agents in liver MRI are shown.

Source link: https://doi.org/10.1016/j.carj.2016.10.008


Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study

Purpose: The aim of this research is to determine the diagnostic efficacy and safety of gadoxetate dimeglumine in patients with confirmed or suspected focal liver disease. All patients, patients with liver cancer, patients with cirrhosis, and patients with HCC + cirrhosis were recruited and classified in 4 a priori designated subgroups: all patients, patients with liver cancer, patients with cirrhosis, and patients with HCC + cirrhosis. While the overall improvement in sensitivity among all four patient groups was similar to gadoxetate disodium and gadobenate dimeglumine, some subgroups showed significant differences. In comparison to gadobenate dimeglumine, there was a significant rise in sensitivity for gadoxetate disodium in patients with HCC and HCC + cirrhosis. In patients with HCC and liver cirrhosis, there were some significant differences over gadobenate dimeglumine for increased sensitivity and specificity in liver lesion detection.

Source link: https://doi.org/10.1177/1178623x19827976


Brain penetration and neurological effects of gadobenate dimeglumine in the rat

Methods: Sprague Dawley rats with an osmotically disrupted BBB were awarded 0. 3 mmol/kg of GD, i. v. , indicating that they were osmotically impaired BBB had 0. 41 mmol/kg of GD, i. v. After i. v. , brain activity of the gadobenate ion was about 60 nmol/g tissue. Following an intractable needle injection, the lowest dose of GD capable of marginally impairing motor coordination in rats with an intact BBB was 0. 01 mmol/kg. BBB results in brain levels of the gadobenate ion that are more than 20 times lower than those obtained following intrathecal administration of the minimally effective dose, as determined by the Rota-rod test.

Source link: https://doi.org/10.1080/02841859709172061


Myocardial T1 mapping and determination of partition coefficients at 3 tesla: comparison between gadobenate dimeglumine and gadofosveset trisodium

Methods and Methods: Study subjects underwent two imaging sessions for T1 mapping at 3 tesla with a modified look-locker inversion recovery pulse sequence to produce one pre-contrast T1 map and two comparison T1 maps. The partition coefficient was higher for gadobenate than gadofosveset, indicating slower blood pool washout for gadofosveset than for gadobenate, rather than for gadobenate. Partition coefficients were considerably lower for the intravascular contrast agent and not for the extravascular agent in comparison to the extravascular contrast agent in normal clinical doses.

Source link: https://doi.org/10.1590/0100-3984.2016.0071


A Comparison between Gadofosveset Trisodium and Gadobenate Dimeglumine for Steady State MRA of the Thoracic Vasculature

Retrospective comparison of gadofosveset trisodium and gadobenate dimeglumine steady state magnetic resonance angiography of the thoracic vasculature at 1. 5 T using signal-to-noise ratio and vessel edge sharpness as indicators of image quality. Mean vessel ES for gadofosveset and gadobenate groups was not significant different, according to the same study. With gadobenate dimeglumine, similar to that obtained with the blood pool agent gadofosveset trisodium, imaging can be started quickly after contrast injection.

Source link: https://doi.org/10.1155/2014/625614

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions